The messaging app was purchased by Facebook in 2014 for a whopping $22 billion. But since the purchase of WhatsApp, cofounders Brian Acton and Jan Koum have had a string of disagreements with Facebook’s upper management over its insistence on monetizing users and their data. Ultimately the differences led both founders to leave the company—a move that cost Acton $850 million. Today he gave his first interview since he tweeted, “It is time. #deletefacebook” back in March. Here’s what he said.
It’s just business: “They are businesspeople, they are good businesspeople. They just represent a set of business practices, principles and ethics, and policies that I don’t necessarily agree with.”
Money over quality: “This is what I hated about Facebook and what I also hated about Yahoo. If it made us a buck, we’d do it.”
On speaking to EU regulators about antitrust worries: “I was coached to explain that it would be really difficult to merge or blend data between the two systems.” But that wasn’t true. He found out there were “plans and technologies to blend data.” ... “I think everyone was gambling because they thought that the EU might have forgotten because enough time had passed.”
Cutting his losses: “It was like, okay, well, you want to do these things I don’t want to do. It’s better if I get out of your way. And I did.”
Going against his beliefs: “At the end of the day, I sold my company. I sold my users’ privacy to a larger benefit. I made a choice and a compromise. And I live with that every day.”
“I am a sellout. I acknowledge that.”
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.